公开(公告)号：US20170320821A1

公开(公告)日：2017-11-09

申请号：US15659760

申请日：2017-07-26

申请人： KISSEI PHARMACEUTICAL CO., LTD.

发明人： Hitoshi Inoue ,  Kohsuke Ohno ,  Tetsuya Nakamura ,  Yusuke Ohsawa

IPC分类号： C07D205/04

CPC分类号： C07D205/04

摘要： [Problem] The present invention provides a novel compound having an S1P1 receptor antagonistic activity.[Solution] The present invention provides a compound represented by the general formula (I): (in the formula, Rl, R2 and R3 are each a hydrogen atom, a halogen atom, a C1-6 alkyl group, a halo C1-6 alkyl group or the like, R4 is a C1-6 alkyl group or the like, R5 is a C1-6 alkyl group or the like, R6 is a C1-6 alkyl group or the like, R7 is a hydrogen atom, a halogen atom, a C1-6 alkyl group or the like, R8 is a halogen atom, a C1-6 alkyl group, a halo C1-6 alkyl group, a C1-6 alkoxy group or the like, and R9 is a hydrogen atom or a C1-6 alkyl group.) or a pharmaceutically acceptable salt thereof, a pharmaceutical compositions containing same, and use thereof. The compounds of the present invention have an excellent S1P1 receptor antagonistic activity and therefore are useful as an agent for the treatment or prevention of antoimmune diseases and the like.

公开(公告)号：US09718771B2

公开(公告)日：2017-08-01

申请号：US15121522

申请日：2015-02-27

申请人： Kissei Pharmaceutical Co., Ltd.

发明人： Hitoshi Inoue ,  Kohsuke Ohno ,  Tetsuya Nakamura ,  Yusuke Ohsawa

IPC分类号： C07D205/04

CPC分类号： C07D205/04

摘要： A compound having an S1P1 receptor antagonistic activity. A compound represented by general formula (I): (in the formula, R1, R2 and R3 are each a hydrogen atom, a halogen atom, a C1-6 alkyl group, a halo C1-6 alkyl group or the like, R4 is a C1-6 alkyl group or the like, R5 is a C1-6 alkyl group or the like, R6 is a C1-6 alkyl group or the like, R7 is a hydrogen atom, a halogen atom, a C1-6 alkyl group or the like, R8 is a halogen atom, a C1-6 alkyl group, a halo C1-6 alkyl group, a C1-6 alkoxy group or the like, and R9 is a hydrogen atom or a C1-6 alkyl group.) or a pharmaceutically acceptable salt thereof, a pharmaceutical compositions containing same, and use thereof. The compounds have an excellent S1P1 receptor antagonistic activity and are useful for the treatment or prevention of autoimmune diseases.

公开(公告)号：US09988350B2

公开(公告)日：2018-06-05

申请号：US15659760

申请日：2017-07-26

申请人： KISSEI PHARMACEUTICAL CO., LTD.

发明人： Hitoshi Inoue ,  Kohsuke Ohno ,  Tetsuya Nakamura ,  Yusuke Ohsawa

IPC分类号： C07D205/04

CPC分类号： C07D205/04

摘要： The present invention provides a compound represented by the general formula (I): in the formula, R1, R2 and R3 are each a hydrogen atom, a halogen atom, a C1-6 alkyl group, a halo C1-6 alkyl group or the like, R4 is a C1-6 alkyl group or the like, R5 is a C1-6 alkyl group or the like, R6 is a C1-6 alkyl group or the like, R7 is a hydrogen atom, a halogen atom, a C1-6 alkyl group or the like, R8 is a halogen atom, a C1-6 alkyl group, a halo C1-6 alkyl group, a C1-6 alkoxy group or the like, and R9 is a hydrogen atom or a C1-6 alkyl group, or a pharmaceutically acceptable salt thereof. The compounds of the present invention have an excellent S1P1 receptor antagonistic activity and therefore are useful as an agent for the treatment or prevention of autoimmune diseases and the like.

公开(公告)号：US20160362368A1

公开(公告)日：2016-12-15

申请号：US15121522

申请日：2015-02-27

申请人： KISSEI PHARMACEUTICAL CO., LTD.

发明人： Hitoshi Inoue ,  Kohsuke Ohno ,  Tetsuya Nakamura ,  Yusuke Ohsawa

IPC分类号： C07D205/04

CPC分类号： C07D205/04

摘要： [Problem] The present invention provides a novel compound having an S1P1 receptor antagonistic activity.[Solution] The present invention provides a compound represented by the general formula (I): (in the formula, R1, R2 and R3 are each a hydrogen atom, a halogen atom, a C1-6 alkyl group, a halo C1-6 alkyl group or the like, R4 is a C1-6 alkyl group or the like, R5 is a C1-6 alkyl group or the like, R6 is a C1-6 alkyl group or the like, R7 is a hydrogen atom, a halogen atom, a C1-6 alkyl group or the like, R8 is a halogen atom, a C1-6 alkyl group, a halo C1-6 alkyl group, a C1-6 alkoxy group or the like, and R9 is a hydrogen atom or a C1-6 alkyl group.) or a pharmaceutically acceptable salt thereof, a pharmaceutical compositions containing same, and use thereof. The compounds of the present invention have an excellent S1P1 receptor antagonistic activity and therefore are useful as an agent for the treatment or prevention of autoimmune diseases and the like.